Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2026-02-19 @ 4:50 PM
Study NCT ID:
NCT00741169
Status:
COMPLETED
Last Update Posted:
2013-04-18
First Post:
2008-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
Sponsor:
Tibotec Pharmaceuticals, Ireland
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-06
Start Date Type:
None
Primary Completion Date:
2008-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-12
Completion Date Type:
ACTUAL
First Submit Date:
2008-08-22
First Submit QC Date:
None
Study First Post Date:
2008-08-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-04-17
Last Update Post Date:
2013-04-18
Last Update Post Date Type:
ESTIMATED